

Keep this card with you and show to any healthcare professional involved in your medical care – for example, your pharmacist, or an emergency doctor.

You should know about certain side effects and topics listed here, talk to your doctor if you get any side effects.

Your name:

Doctor's name

(who prescribed Cibinqo):

Doctor's phone number:

The date you started Cibinqo:



This medicine is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side effects you may get. See www.mhra.gov.uk/yellowcard or search MHRA Yellow Card in the Google Play or Apple App Store for how to report side effects.



Cibinqo ▼ (abrocitinib)

PATIENT CARD

Safety Information for Patients about Cibinqo

- This card contains important safety information you should be aware of before and during treatment with Cibinqo.
- For more information read the patient information leaflet included in each pack of Cibinqo.
- Ask your doctor or pharmacist if any of the information is not clear.

PP-CIB-GBR-0755. April 2023
Copyright © 2023 Pfizer Limited

What Cibinqo is and what it is used for:

Cibinqo contains the active substance abrocitinib. It belongs to a group of medicines called Janus kinase inhibitors, which help to reduce inflammation. It works by reducing the activity of an enzyme in the body called 'Janus kinase', which is involved in inflammation.

Cibinqo is used to treat adults and adolescents 12 years and older with moderate-to-severe atopic dermatitis, also known as atopic eczema.

Laboratory tests

Your doctor will ask you to get laboratory tests (including testing for high cholesterol) before starting Cibinqo and while you are taking Cibinqo and may adjust your treatment accordingly.

You should know about certain side effects and topics listed below, talk to your doctor if you get any side effects:

Risk of infections

Talk to your doctor or pharmacist before and during the treatment with Cibinqo if you get symptoms such as fever, painful rash, cold sores around the lips, nausea, vomiting or diarrhoea, shortness of breath as these can be signs of infection.

Risk of blood clots in veins or lungs:

Talk to your doctor or pharmacist if you get sudden shortness of breath or difficulty breathing, chest pain or pain in upper back, swelling of the leg or arm, leg pain or tenderness, or redness or discoloration in the leg or arm as these can be signs of blood clots in the veins.

Risk of heart disease:

Talk to your doctor or pharmacist before and during the treatment if you develop severe chest pain or tightness (that may spread to arms, jaw, neck and back), shortness of breath, cold sweat, light headedness or sudden dizziness, as these may be signs of a heart attack.

Risk of cancer:

Talk to your doctor or pharmacist before taking Cibinqo if you have or have had cancer, smoke or have smoked in the past, because your doctor will discuss with you if Cibinqo is appropriate for you. Non-melanoma skin cancer has been observed in patients taking Cibinqo. Your doctor may recommend that you have regular skin examinations while taking Cibinqo. If new skin lesions appear during or after therapy or if existing lesions change appearance, tell your doctor.

Vaccines:

Talk to your doctor or pharmacist if you have recently had or plan to have a vaccination (immunisation) this is because live vaccines are not recommended while using Cibinqo.

Pregnancy, contraception and breast-feeding

- If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine.
- Do not use Cibinqo while breast-feeding as it is not known if this medicine passes into milk. You and your doctor should decide if you will breast-feed or use this medicine.
- If you are a woman of childbearing potential, you should use an effective method of contraception to avoid becoming pregnant during treatment with Cibinqo and for at least 1 month after your last treatment dose. You must tell your doctor if you become pregnant as this medicine should not be used during pregnancy.